fMRI-based Biomarkers for Multiple Components of Pain

基于功能磁共振成像的多种疼痛生物标志物

• 批准号: 8916319
• 负责人: TOR D. WAGER
• 金额: $ 16万
• 依托单位: UNIVERSITY OF COLORADO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8916319
• 关键词: Acute; Address; Affect; Affective; Algorithms; Analgesics; Arthritis; Back; Biological Markers; Brain; Brain Mapping; Clinical; Clinical Research; Clinical Trials; Cognitive; Complex; Data; Data Set; Decision Making; Development; Diagnosis; Disease; Distress; Emotional; Event; Fright; Functional Magnetic Resonance Imaging; Functional disorder; Funding; Goals; Grant; Health; Heating; Human; Hyperalgesia; Hypersensitivity; Image; Individual; Individual Differences; Intervention; Laboratories; Laboratory Procedures; Light; Machine Learning; Measures; Mechanics; Medicine; Mental disorders; Minority; Modality; Modeling; Naproxen; Nerve Pain; Nociception; Pain; Pain Measurement; Pain intensity; Pain quality; Painless; Pathology; Patient Self-Report; Patients; Pattern; Pelvis; Performance; Peripheral; Persons; Physicians; Placebos; Population; Process; Recording of previous events; Reporting; Research; Research Personnel; Sampling; Sensitivity and Specificity; Site; Societies; Specificity; Stimulus; Symptoms; System; Techniques; Testing; Time; Touch sensation; Translating; Treatment Effectiveness; Validation; Visceral; Visual; Work; allodynia; base; chronic pain; clinical practice; cost; design; distraction; duloxetine; expectation; experience; improved; mental imagery; neuropathology; neurophysiology; painful neuropathy; patient population; psychologic; relating to nervous system; remifentanil; research study; response; social; spontaneous pain; success

DESCRIPTION (provided by applicant): Objective biomarkers of pathology exist for a number of diseases, and their development is one of the great advances of modern allopathic medicine. However, objective assessment of pain and other mental health disorders has lagged far behind. Pain cannot be explained by peripheral damage alone; it is caused by a variety of neuropathological processes, which has made it difficult to assess and treat. Currently, the only acceptable way to measure pain is by self-report, which presents a serious barrier to effective research and treatment. Self-reported pain is influenced by nociceptive, affective, and cognitive decision-making processes-and though there are many treatments that can influence reported pain, they likely do so through a heterogeneous set of neurophysiological mechanisms, with different consequences for health and long-term well being. As a result, in spite of a long history of research, current treatments for pain are effective for a minority of individuals, with enormous costs to patients and to society. Biomarkers for physical pain could dramatically improve diagnosis and treatment, by allowing pain to be characterized on the basis of underlying neuropathology, rather than external symptoms. They could also improve treatment, by allowing interventions to be targeted to type of neuropathology involved. Biomarkers that can shed light on the brain pathophysiology that causes pain must necessarily rely on direct measures of brain function. In the past several years, major advances in combining functional magnetic resonance imaging (fMRI) with machine learning techniques-algorithms for finding predictive patterns in complex datasets-have brought the goal of fMRI-based pain assessment within reach. In preliminary data, we show for the first time that fMRI activity can predict whether an individual person is experiencing high or low physical pain with over 90% sensitivity and specificity. Critically, the biomarker is specific to physical pain when compared with non-painful touch and several classes of salient, affective events. In addition, it achieves this level of accuracy when applied prospectively to new samples, across different scanners and paradigms. This preliminary success raises a number of issues that must be addressed before fMRI-based biomarkers can be used in large-scale clinical trials and clinical practice, including a) robustnes across laboratories and procedures, b) specificity to body site, modality, and quality of pain, c) responses to analgesic treatment, and d) applicability to spontaneous and acute hypersensitivity/allodynia in clinical populations. Here, we propose to aggregate existing data across a consortium of researchers, allowing more extensive tests of sensitivity and specificity across 13 fMRI studies in healthy individuals and 18 studies in diverse clinical pain populations. In addition, we will conduct five new experiments to address critical aspects of biomarker performance. These data will allow us to develop and validate new, more comprehensive biomarkers that can assess multiple aspects of pain across healthy individuals and chronic pain sufferers.

描述（由申请人提供）：客观的病理生物标志物存在于许多疾病中，它们的发展是现代对抗疗法医学的伟大进步之一。然而，对疼痛和其他精神健康障碍的客观评估远远落后。疼痛不能仅仅用外周损伤来解释；它是由多种神经病理过程引起的，这使得它难以评估和治疗。目前，唯一可以接受的测量疼痛的方法是自我报告，这对有效的研究和治疗构成了严重的障碍。自我报告的疼痛受到伤害、情感和认知决策过程的影响，尽管有许多治疗方法可以影响所报告的疼痛，但它们可能是通过一套异质的神经生理机制来实现的，对健康和长期福祉有不同的影响。因此，尽管历史悠久